Compare DexCom, Inc. (DXCM) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kohl's Corporation — how do they compare? DexCom, Inc. trades at $77.41 (market cap $28.06B), while Kohl's Corporation trades at $17.69 (market cap $1.94B). The key difference: DexCom, Inc. is far larger — about 14.5× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.92% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | KSS | |
|---|---|---|
Market Cap | $28.06B | $1.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $24.71 |
52-Week Low | $54.84 | $9.39 |
Enterprise Value | $27.03B | $8.04B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Kohl's (KSS) trades at $17.62, up 7.31% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows deep value with a P/E of 7.18 and P/B of 0.48, while recent earnings beats and a 10% jump in juniors sales (Zacks, 2026-06-30) signal early turnaround progress. Cash flow improved to $276M net in 2026 from -$49M in 2025, though revenue has declined from $19.4B in 2022 to $16.2B in 2025.
The outlook hinges on successful execution of Kohl's value-focused strategy and proprietary brand growth to reverse sales declines. Risks include intense retail competition and macroeconomic pressure on consumer spending. Analysts are mixed with a $16.75 consensus target below the current price, suggesting cautious optimism amid restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
